跳至主要内容
临床试验/NL-OMON38607
NL-OMON38607已完成不适用

A pilot study on efficacy and safety of 100 ug start dose wasp venom immunotherapy (VIT) - EVVIT100

niversitair Medisch Centrum Groningen0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - A positive history of a systemic response grade II/III/IVa after vespid sting
  • - Specific serum IgE > 0.7 kU/
  • - Positive intracutaneous skin test for vespid venom ( at <= 1 µg/ml)

排除标准

  • - A positive history of a systemic response grade IVb according to Müller after a vespid sting
  • - Age under 18 years or above 65 years
  • - Severe cardiopulmonary disease (clinical evidence of congestive heart failure, coronary disease or severe hypertension)
  • - Insufficiently controlled asthma, especially if FEV1 is 70% of predicted.
  • - Conditions that influence the immune system (immune deficiencies, malignancy, auto-immune diseases)
  • - Severe kidney failure
  • - Interfering medication with the outcome or recovery from a systemic reaction (β-blockers and immunosuppressive drugs)
  • - Allergy to auxiliary matter in Pharmalgen® Vespula spp.
  • - Pregnancy
  • - Mastocytosis

研究者

相似试验